Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.
There is no investment information
No recent news or press coverage available for Provectus Biopharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
